APA (7th ed.) Citation

Cho, Y., Lee, S. H., Jung, J. H., Lim, H., & Bae, K. (2017). Bioequivalence of the Highest Dose Strength Fixed-Dose Combination Tablet Of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects. Clinical therapeutics, 39(8), e53. https://doi.org/10.1016/j.clinthera.2017.05.165

Chicago Style (17th ed.) Citation

Cho, Y.-S, S. Hyang Lee, J. Hyuk Jung, H.-S Lim, and K.-S Bae. "Bioequivalence of the Highest Dose Strength Fixed-Dose Combination Tablet Of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects." Clinical Therapeutics 39, no. 8 (2017): e53. https://doi.org/10.1016/j.clinthera.2017.05.165.

MLA (9th ed.) Citation

Cho, Y.-S, et al. "Bioequivalence of the Highest Dose Strength Fixed-Dose Combination Tablet Of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects." Clinical Therapeutics, vol. 39, no. 8, 2017, p. e53, https://doi.org/10.1016/j.clinthera.2017.05.165.